AstraZeneca plc (AZN) Ordinary US$0.25

Sell:11,816.00pBuy:11,820.00p66.00p (0.56%)

FTSE 100:0.42%
Market closed |
Prices delayed by at least 15 minutes
Sell:11,816.00p
Buy:11,820.00p
Change:66.00p (0.56%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:11,816.00p
Buy:11,820.00p
Change:66.00p (0.56%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.

Key people

Pascal Soriot
Chief Executive Officer, Executive Director
Aradhana Sarin
Chief Financial Officer, Executive Director
Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Jeffrey A. Pott
Chief Human Resources Officer, Chief Compliance Officer, General Counsel
Sharon Barr
Executive Vice President - BioPharmaceuticals R&D
Pam P. Cheng
Executive Vice President - Global Operations, Information Technology and Chief Sustainability Officer
Ruud Dobber
Executive Vice President - BioPharmaceuticals Business Unit
David Fredrickson
Executive Vice President - Oncology Business Unit
Susan Galbraith
Executive Vice President - Oncology and Research and Development
Iskra Reic
Executive Vice President, International
Michel Demare
Non-Executive Independent Chairman of the Board
Birgit M. Conix
Non-Executive Director
Rene Haas
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Euan Ashley
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    AZN
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB0009895292
  • Market cap
    £183.08bn
  • Employees
    94,300
  • Shares in issue
    1.55bn
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, FTSE 100 Index, SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.